The goal of the study is to evaluate whether sitagliptin can affect postprandial lipoprotein metabolism in type 2 diabetic patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
3
sitagliptin 100 mg/d for 10 weeks
glimepiride 1 mg/d for 10 weeks
Medical Dept. 2, Grosshadern, University Munich
Munich, Germany
incremental area under the triglyceride curve (iAUC-TG)
incremental area under the plasma triglyceride concentration curve following a standardized oral fat challenge
Time frame: 10 weeks
LDL-cholesterol
fasting LDL-cholesterol
Time frame: 10 weeks
HDL-cholesterol
fasting HDL-cholesterol
Time frame: 10 weeks
VLDL-cholesterol
fasting VLDL-cholesterol
Time frame: 10 weeks
triglycerides
fasting triglycerides
Time frame: 10 weeks
area under the triglyceride curve (AUC-TG)
area under the plasma triglyceride concentration curve following a standardized oral fat challenge
Time frame: 10 weeks
area under the VLDL-triglyceride curve (AUC-VLDL-TG)
area under the plasma VLDL-triglyceride concentration curve following a standardized oral fat challenge
Time frame: 10 weeks
incremental area under the VLDL-triglyceride curve (iAUC-VLDL-TG)
incremental area under the plasma VLDL-triglyceride concentration curve following a standardized oral fat challenge
Time frame: 10 weeks
glucose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
fasting glucose concentration
Time frame: 10 weeks
insulin
fasting insulin concentration
Time frame: 10 weeks
HOMA
Time frame: 10 weeks
HbA1c
Time frame: 10 weeks
interleukin-6
Time frame: 10 weeks
hs-CRP
Time frame: 10 weeks